Press Release No. 020/KFCP-DIR/PR/V/20
Jakarta, May 27, 2020, PT Kalbe Farma Tbk (Kalbe) signed a memorandum of understanding with Genexine, Inc., a biological drug company from South Korea to develop a vaccine for the new corona virus or Covid-19 . Kalbe and Genexine has agreed to conduct GX-19 clinical trials in Indonesia, that is the development of DNA vaccines against new corona virus, to be carried out by the consortium of Genexine, Binex, the International Vaccine Institute (IVI), GenNBio, the Korea Advanced Institute of Science & Technology (KAIST), and Pohang University of Science & Technology (POSTECH). Covid-19 vaccine clinical trial is planned to be conducted in June 2020.
“The Covid-19 vaccine development collaboration is Kalbe's contribution to helping the government to overcome the Covid-19 pandemic in Indonesia,” said Sie Djohan, Director of PT Kalbe Farma Tbk, “Kalbe hopes that through the research and development efforts the Covid-19, the vaccine will be able to get quick results, thus the availability of vaccines in Indonesia can be guaranteed,” continued Sie Djohan.
The vaccine research itself has been carried out on Primates, and has been shown to have produced antibodies capable of neutralizing the New Corona virus, thus continues to the next stage of being tested on humans.
Furthermore, Sie Djohan also added that Kalbe will collaborate with relevant government agencies to collaborate in developing the Covid-19 vaccine so that the research process will run smoothly and the results can be utilized for the benefit of the health of the Indonesian people.
PT Kalbe Farma Tbk is known to have a cooperation with a South Korean biological drug company, Genexine Inc. through the formation of PT Kalbe Genexine Biologic (KGBio), a joint venture company that is developing and making raw materials for biotechnology medicines in Indonesia.
Kalbe at a glance
PT Kalbe Farma Tbk (“Kalbe”) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines (Cefspan, Brainact, Broadced, etc. ); over-the-counter medication division (Promag, Mixagrip, Komix, Woods, Fatigon, etc. ); energy and ready-to-consume supplement drinks (Hydro Coco, Extra Joss, Nitros); nutrition division (ChilKid, Prenagen, Diabetasol, etc); and distribution and logistics division. Kalbe currently has approximately 40 subsidiaries and 12 production facilities with international standard, and employs approximately 17,000 employees dispersed across more than 74 branches throughout Indonesia. Since 1991, Kalbe has been listed at the Indonesia Stock Exchange, with ticker code: KLBF.